(Press-News.org) Highlights:
Antimicrobial resistance is a growing issue in aquaculture.
Vaccines don’t work on fish larvae because they have no developed immune system, so alternatives are necessary.
Researchers in Denmark discovered that mixtures of bacteria from live-feed microalgae are capable of inhibiting fish pathogens.
Washington, D.C.—A new study by Danish researchers has demonstrated that it is possible to develop a consortium of bacteria that can inhibit bacterial pathogens in aquaculture. This could potentially reduce the use of antibiotics in aquaculture and possibly other applications. The study was published in Microbiology Spectrum, a journal of the American Society for Microbiology.
In the new study, researchers set out to find and develop non-antibiotic biological disease control and prevention options for aquaculture. Aquaculture is the fastest growing food-protein producing sector in the world and the carbon footprint is lower than that of many animal husbandry sectors. Aquaculture, like other intensive productions, is challenged by infectious disease outbreaks. Most commonly, these are caused by bacterial agents and can, to some extent, be treated with antibiotics. However, the alarming rise and spread of antibiotic-resistant bacteria calls for alternative treatments. While vaccines can be an excellent strategy, these do not work on fish larvae that have no developed immune system. Using beneficial bacteria or probiotics to combat pathogens is a strategy becoming widespread in both animal rearing and horticulture.
The researchers developed an in vitro assay to evaluate the anti-pathogen efficacy of mixed algal microbiomes from the live-feed microalgae Tetraselmis suecica and Isochrysis galbana. The scientists wanted to find combinations of beneficial bacteria, since they believe that the anti-pathogen effect is likely stronger in a combination. “To test if the pathogen could be inhibited by a mixture of other bacteria, we needed a measure of the growth (and growth inhibition of the pathogen), so we tagged the fish pathogen with a green fluorescent protein. By measuring this—and the reduction in fluorescence— we could identify bacterial communities that inhibited the pathogen,” said corresponding study author Lone Gram, Ph.D., professor in the Department of Biotechnology and Biomedicine, Technical University of Denmark.
The researchers found that mixtures of bacteria could inhibit Vibrio anguillarum, a fish pathogen, and subsequently isolated pure cultures of bacteria. They found that some of these bacteria only inhibited the fish pathogen when combined, not alone, demonstrating that some bacteria were stronger together.
“We have shown that it is possible in microbiomes (in our case, the microbiome of algae used as live feed in aquaculture) to find mixtures of bacteria that can inhibit the pathogen,” Gram said, “thus paving the way for engineering microbiomes that can inhibit bacterial pathogens and reduce the need for use of antibiotics. We can then reduce the spread of antibiotic-resistant bacteria.”
###
The American Society for Microbiology is one of the largest professional societies dedicated to the life sciences and is composed of over 37,000 scientists and health practitioners. ASM's mission is to promote and advance the microbial sciences.
ASM advances the microbial sciences through conferences, publications, certifications, educational opportunities and advocacy efforts. It enhances laboratory capacity around the globe through training and resources. It provides a network for scientists in academia, industry and clinical settings. Additionally, ASM promotes a deeper understanding of the microbial sciences to all audiences.
END
Natural algal communities can inhibit aquaculture pathogens
2025-05-21
ELSE PRESS RELEASES FROM THIS DATE:
Wind-related hurricane losses for homeowners in the southeastern U.S. could be nearly 76 percent higher by 2060
2025-05-21
Herndon, VA, May 21, 2025 -- Hurricane winds are a major contributor to storm-related losses for people living in the southeastern coastal states. As the global temperature continues to rise, scientists predict that hurricanes will get more destructive -- packing higher winds and torrential rainfall. A new study, published in the journal Risk Analysis, projects that wind losses for homeowners in the Southeastern coastal states could be 76 percent higher by the year 2060 and 102 percent higher by 2100.
University of Illinois civil engineer ...
Mount Sinai experts to present new research on AI models that predict chronic respiratory failure and detect airway obstruction at ATS 2025 International Conference
2025-05-21
World renowned pulmonologists and experts in respiratory medicine from the Mount Sinai Health System will present new research at the American Thoracic Society (ATS) 2025 International Conference in San Francisco from May 18–May 21. Please let me know if you would like to coordinate an interview about their work. Mount Sinai doctors and researchers are also available to comment on breaking news and trending topics.
Sessions and Symposiums
*All abstracts listed below are under embargo until the scheduled ...
Study finds pneumonia computerized clinical decision support reduces mortality disparities in patients facing economic hardships
2025-05-21
In a new study, researchers from Intermountain Health in Salt Lake City have shown that by using a computerized clinical decision support tool to guide diagnosis and treatment in emergency department patients with pneumonia, they were able to reduce mortality rates, especially in patients experiencing socioeconomic hardships.
Pneumonia, a serious infection in the lungs that causes inflammation and difficulty breathing, is one of the most common causes of death worldwide. An estimated 150,000 people are hospitalized annually for pneumococcal pneumonia, ...
Mount Sinai researchers uncover a promising new way to modulate brain cell activity to potentially treat major depressive disorder in adults
2025-05-21
A mechanism involving potassium channels in the brain that control brain cell activity could provide a new and fundamentally different way of treating depression symptoms in adults with major depressive disorder, according to two complementary papers published recently by researchers at the Icahn School of Medicine at Mount Sinai.
In two new research articles, published in Biological Psychiatry and Molecular Psychiatry, the researchers provide new insights into how a drug called ezogabine may impact the brain to improve depression.
“Depression is a devastating ...
New clues to autism: epigenetic study identifies RABGGTB as a novel candidate gene
2025-05-21
Autism spectrum disorder (ASD) is a condition affecting the brain’s development and often affects the ability of a person to perceive sensory information and social cues and socialize with others. Recent studies have revealed that environmental factors and epigenetic processes, such as DNA methylation, are crucial to the development of ASD. Notably, immune activation and exposure to stress hormones are known to alter neuronal activity in the dorsal raphe (DR, a region of the brain involved in serotonin signaling), contributing ...
EuroPCR 2025 – Meta-analysis of individual patient data from the PROTECTED TAVR and BHF PROTECT-TAVI trials
2025-05-21
Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among which is the meta-analysis of data from the PROTECTED TAVR and BHF PROTECT TAVI Trials
Background
The embolisation of debris after transaortic valve implantation (TAVI) for the treatment of aortic stenosis can lead to stroke. Cerebral embolic protection (CEP) devices, which can capture this debris and thus lower the incidence of stroke, have been deployed during ...
EuroPCR 2025 – The FAITAVI trial: angiography versus physiology-guided PCI in patients undergoing TAVI – 12-month follow-up data
2025-05-21
Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the FAITAVI randomised clinical trial (RCT).
Background
The optimal management of patients with intermediate coronary artery disease (CAD) and severe aortic stenosis (AS) who are candidates for TAVI remains unclear. Recent trials comparing percutaneous coronary intervention ...
EuroPCR 2025 – One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
2025-05-21
Background
While dual antiplatelet therapy (DAPT) has long been the standard of care for the management of acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), there is an increasing awareness of the need to find a more patient-centred approach that strikes a balance between the ischaemic protection DAPT offers and the risk of bleeding complications it can create.
The effect of DAPT in dosage and duration on cardiovascular events and bleeding after implantation of drug-coated stents (DCS) in ACS patients, ...
PREVENT equation accurately estimated 10-year CVD risk and those with calcium buildup
2025-05-21
Research Highlights:
The American Heart Association’s PREVENTTM risk calculator accurately identified participants who had calcium buildup in their heart arteries and those who had a higher future heart attack risk, in an analysis of about 7,000 adults in New York City referred for heart disease screening.
The PREVENT scores also predicted future heart attack risk.
Embargoed until 4 a.m. CT/5 a.m. ET Wednesday, May 21, 2025
DALLAS, May 21, 2025 — The PREVENTTM risk calculator helped to identify people with plaque buildup in the arteries of the heart, in addition to predicting their risk of a future heart attack, according ...
Nano-engineered thermoelectrics enable scalable, compressor-free cooling
2025-05-21
Researchers at the Johns Hopkins Applied Physics Laboratory (APL) in Laurel, Maryland, have developed a new, easily manufacturable solid-state thermoelectric refrigeration technology with nano-engineered materials that is twice as efficient as devices made with commercially available bulk thermoelectric materials. As global demand grows for more energy-efficient, reliable and compact cooling solutions, this advancement offers a scalable alternative to traditional compressor-based refrigeration.
In a paper published in ...